Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.
Cluster 2 patients exhibited ‘a more severe form of the disease, marked with frequent serositis and haematological manifestations, renal and neurological involvement,’ and had poorer outcomes over time.
"Readers should not have to infer what was probably done; they should be told explicitly." This principle drives the comprehensive CONSORT 2025 update, with its 7 new checklist items aimed at improving clinical trial transparency.
Researchers found most FDA-authorized COVID-19 treatments were not linked to serious adverse events, though risks may rise with tocilizumab or convalescent plasma in specific patients.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
A humanized monoclonal antibody that targets CD19+ B cells is first FDA-approved treatment for immunoglobulin G4–related disease, reducing flare risk and glucocorticoid use in clinical trials.
New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.
Individuals with autoimmune arthritides are more likely to experience mood and anxiety disorders—even relative to counterparts with other chronic illnesses—according to a national cohort study.